Category: Publications

GnRH Receptor Antagonist Mono- And Combination Therapy With E2/NETA Add-Back – Pharmacodynamics And Safety Of OBE2109

Posted on by Sylwia Scheel-Krüger

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E.

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E. Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109. J Clin Endocrinol Metab. 2018;103(2):497‐504. doi:10.1210/jc.2017-01875

Confirmation of the Cardiac Safety of OBE022 in a First in Human Study in Healthy Subjects using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity

Posted on by Sylwia Scheel-Krüger

J. Täubel, U. Lorch , G. Ferber , O Pohl

ACCP Conference, 17-19 September 2017, San Diego, CA
Poster 019: Page 16

Volume6, IssueS1, Special Issue: 2017 Annual Meeting American College of Clinical Pharmacology, September 2017, doi:full/10.1002/cpdd.385

A placebo-controlled, randomized, double-blind study of pregnancy and live birth rates after single oral administration of a novel oxytocin antagonist, nolasiban, prior to embryo transfer

Posted on by Sylwia Scheel-Krüger

H. Tournaye, A. Humberstone, V. Lecomte, P. Terrill, P. Pierzynski, E. Loumaye

ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract O-024: Page i12

Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology, Human Reproduction, Volume 32, Issue suppl_1, July 2017, Pages i1–i539

Combination tocolytics on the inhibition of OT-induced contractions of human pregnant myometrium in vitro

Posted on by Sylwia Scheel-Krüger

L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou

ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract O-119: Page i54

Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology, Human Reproduction, Volume 32, Issue suppl_1, July 2017, Pages i1–i539

FP receptor antagonist, OBE002, inhibits both PGF2α- and OT-induced contractions of human pregnant myometrium in vitro

Posted on by Sylwia Scheel-Krüger

L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou

ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract P-692: Page i452

Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology, Human Reproduction, Volume 32, Issue suppl_1, July 2017, Pages i1–i539

Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor–Mediated Signaling in Human Amnion and Myometrium

Posted on by Sylwia Scheel-Krüger

Sung Hye Kim, Oliver Pohl, Andre Chollet, Jean-Pierre Gotteland, Adam D. J. Fairhurst, Phillip R. Bennett, and Vasso Terzidou

Kim SH, Pohl O, Chollet A, et al. Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor-Mediated Signaling in Human Amnion and Myometrium. Mol Pharmacol. 2017;91(4):403‐415. doi:10.1124/mol.116.106013

Both OTR Antagonists, Atosiban and Nolasiban, Inhibits PGE2/PGF2α-Induced Contractions of Human Pregnant Myometrium In Vitro

Posted on by Sylwia Scheel-Krüger

Sung Hye Kim, Hauwa Ahmed, Lucia Riaposova, Oliver Pohl, Andre Chollet, Aylin Hanyaloglu, Phillip R Bennett, Vasso Terzidou

SRI Conference, 15-18 March 2017, Orlando, FL
Abstract S-031: Page 245A

Scientific Abstracts Reproductive Sciences Vol. 24 (1_suppl), 1A-51A, March 2017

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue